Biovailability and the Entourage-Effect are the key to cannabis's effiacy.
The technology PuranoTec® does both.
The CannaXan GmbH provides the pharmaceutical cannabinoid active ingredient CannaXan 701-1.1. It is made from the entire cannabis flower Bedrocan with the PuranoTec manufacturing process for medical use. CannaXan 701-1.1 is a THC-focused SmartLipid and is registered as a pharmaceutical active ingredient in the EUDRACT database by the government of Upper Bavaria. The pharmaceutical cannabinoid active ingredient CannaXan 701-1.1 is processed in the pharmacy into a magistral preparation.
At a later date, CannaXan GmbH will also bring a CBD-focused SmartLipid as a pharmaceutical active ingredient for the production of a magistral preparation to the pharmacies.
A note to patients: For legal reasons, further information on the indication, manufacture, training, prescription of CannaXan prescriptions and the available scientific findings may only be presented to industry, retailers and doctors and pharmacists, but not to the public. If you would like more information about the use of the pharmaceutical active substance CannaXan 701-1.1, detailed information on taking the dose of CannaXan 701-1.1, or everyday information (such as driving ability), please contact your attending physician, who can receive such information from us at any time and discuss it with you.